This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator.
Aims are: (1) to determine efficacy and safety of bevacizumab in patients with unresectable hepatocellular cancer (without tumor invasion of main portal vein or metastasis); (2) to collect information on tumor vascular perfusion kinetics, as determined by dynamic gadolinium-enhanced MRI, before and following bevacizumab therapy; (3) to collect information circulating levels of VEGF and related cytokines which also contribute to HCC pathogenesis and on potential alterations of these levels in the setting of VEGF-inhibition; and (4) to collect information on hepatic function and hepatitis viral activity in cirrhosis and upon potential alterations in the setting of VEGF inhibit
Showing the most recent 10 out of 370 publications